Lifestar Pharma LLC

Wyeth Pharmaceutical manufactures a range of products related to cardiovascular and metabolic diseases, inflammation, biotherapeutics and musculoskeletal biology. It offers research and development programs that are focused on small molecules, vaccines and biotechnology. The division explores more than 90 therapies for medical conditions, such as diabetes, breast cancer, multiple sclerosis, schizophrenia and Alzheimer s disease. It also offers treatment for psychological and physiological health issues. With a location in Pearl River, N.Y., Wyeth Pharmaceutical is owned and operated by Wyeth, which provides biological and pharmaceutical products. The company additionally provides online health-related tools and resources.

Taro Pharmaceuticals USA Inc, located in Mt Pleasant, Town of, NY, is a leading manufacturer and supplier of prescription and over-the-counter pharmaceutical products in the United States. They specialize in topical dermatological products and offer a growing line of solid dosage form products used in cardiology and neurology. Taro is proud to provide millions of Americans with reliable generic pharmaceuticals and over-the-counter private-label products. They also partner with the nonprofit organization, Rx Outreach, to offer a Patient Assistance Program for critically needed medications, ensuring accessibility and affordability for those in need.Generated from the website

The Medicines Company develops products that improve acute hospital care and meets the demands of some of the world's most advanced medical practitioners. The company markets Angiomax for injection, an anticoagulant approved for use in patients undergoing coronary angioplasty procedures. The Medicines Company utilizes its range of clinical and commercial skills to develop products acquired from leading life science innovators. In addition to the approved Angiomax product, The Medicines Company is developing clevidipine, a short-acting calcium channel blocker. The Medicines Company is also conducting significant clinical research to study potential additional indications for Angiomax use. In December of 2003, the Company acquired cangrelor, an anticoagulant that prevents platelet clotting factors from activating, which the company believes has potential uses in coronary angioplasty and cardiac surgery. The Medicines Company has offices in Parsippany, N.J., Waltham, Mass., and Abingdon, United Kingdom.